CClinicalTrials.gg
Not yet recruitingNCT06285656Updated Feb 29, 2024

Femoral Blood Gas and Prediction of Postoperative Bleeding

An observational study in Postoperative Hemorrhage and Blood Transfusion, sponsored by Ankara City Hospital Bilkent. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-29.

Sponsored by Ankara City Hospital Bilkent · Observational

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Postoperative bleeding is still an important concern after major abdominal surgery. Postoperative bleeding is the most important determinant of morbidity and death. It results in longer hospital stays, the necessity for extra radiological tests, interventional radiology treatments, and the possibility of reoperation. Early detection of postoperative bleeding reduces morbidity and mortality with appropriate intervention.Simultaneous arterial and venous blood gas measurements can be used to quickly identify the degree of bleeding and the need for replacement in serious trauma patients brought to the emergency room.Lactate levels, venous oxygen saturation, and the differential in partial pressure of carbon dioxide between arterial and venous blood can all be used to indicate the requirement for replacement, as demonstrated in several studies. The purpose of this study is to evaluate lactate levels, venous oxygen saturation, and arterial-venous partial pressure of carbon dioxide difference in blood gas analysis in order to assess the severity of bleeding in patients undergoing major abdominal surgery as early as possible and perform replacement as soon as possible.

02

Conditions studied

  • Postoperative Hemorrhage
  • Blood Transfusion

Keywords

  • Abdominal Surgery
  • Postoperative Hemorrhage
  • Blood Transfusion
03

In context

Hemorrhage

3,000 studies on the registry are indexed under Hemorrhage; 474 are open to participants now.

This study's planned enrollment of 100 is below the median of 150 across 893 observational studies indexed under Hemorrhage.

Browse Hemorrhage studies →

Lead sponsor

Ankara City Hospital Bilkent is the lead sponsor of 424 studies on the registry; 105 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients will have surgery at Ankara Bilkent City Hospital's General Surgery Clinic and then be transferred to the critical care unit.

Inclusion criteria

  • Patients with major abdominal surgery
  • Postoperative intensive care unit following
  • Accepting to participate in research

Exclusion criteria

Exclusion Criteria:

  • Age under 18 years old
  • Pregnant patients
  • Do not accept to participate of study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
3 Days
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Group 1/

    Patients with postoperative hemmorhagia

  • Grup 2

    Patients without postoperative hemmorhagia

06

What researchers measure

Primary outcomes

  1. Eritrocyte replacement

    could we predict eritrocyte replacement at early postoperative period?

    Time frame: 6 months

Secondary outcomes

  1. Postoperative Hemmorhagea

    Could we predict postoperative hemorrhage in the early postoperative period?

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06285656
Lead sponsor
Ankara City Hospital Bilkent
Responsible party
Sponsor
First posted
Feb 29, 2024
Start date
Mar 1, 2024 (estimated)
Primary completion
Oct 1, 2024 (estimated)
Completion
Oct 3, 2024 (estimated)
Last update
Feb 29, 2024

Study contacts

Hüseyin Fahri Martlı
Contact
fahri_martli@hotmail.com
+905301794699

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion